Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

322.28 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M ↗

August 21, 2023

Krystal Biotech, Inc. (NASDAQ: KRYS) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV)

Via Benzinga

Analyst Ratings for Krystal Biotech ↗

August 08, 2023

Via Benzinga

Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 07, 2023

Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of...

Via Benzinga

Expert Ratings for Krystal Biotech ↗

July 03, 2023

Via Benzinga

What Will AbbVie Buy Next? ↗

June 28, 2023

Two mid-cap drugmakers stand out as logical targets for AbbVie.

Via The Motley Fool

Krystal Biotech Inc. (NASDAQ: KRYS) is a Stock Spotlight on 6/8

June 08, 2023

Via Investor Brand Network

3 Biotech Stocks to Buy Before the Breakout ↗

July 28, 2023

Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch.

Via InvestorPlace

2 Soaring Stocks With More Upside Potential ↗

July 21, 2023

Are these mid-cap stocks giants in the making?

Via The Motley Fool

Arbutus Appoints Two New Executives

July 10, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter ↗

June 06, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Up 48% in 2023, Is This Biotech Stock a Buy? ↗

June 03, 2023

How much longer can this biotech's run last?

Via The Motley Fool

Why Shares of Krystal Biotech Are Rising Monday ↗

May 22, 2023

The company is moving quickly to market its newly approved therapy.

Via The Motley Fool

Analyst Expectations for Krystal Biotech's Future ↗

May 22, 2023

Via Benzinga

Expert Ratings for Krystal Biotech ↗

February 28, 2023

Via Benzinga

Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine ↗

December 15, 2022

Via Benzinga

Krystal Clear: Krystal Biotech Clears Resistance in Good Volume

May 30, 2023

Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem.

Via MarketBeat

Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™

May 23, 2023

From Option Care Health, Inc.

Via GlobeNewswire

Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment ↗

May 22, 2023

The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with

Via Benzinga

Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action

May 22, 2023

Via Investor Brand Network

FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder ↗

May 22, 2023

The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic

Via Benzinga

2 Risky Stocks That Could Soar in 2023 ↗

December 06, 2022

These "exciting" companies aren't for everyone.

Via The Motley Fool

Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles ↗

November 17, 2022

Via Benzinga

NVIDIA To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday ↗

May 22, 2023

Needham cut the price target for Wix.com Ltd. (NASDAQ: WIX) from $125 to $120. Needham analyst Bernie McTernan maintained a Buy rating. Wix.com shares dropped 3.2% to close at $78.09 on Friday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023 ↗

April 18, 2023

Via Benzinga

Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday ↗

February 28, 2023

U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 ↗

February 28, 2023

Via Benzinga

Have A Look At William Blair's Top Biotech Picks For 2023 ↗

December 25, 2022

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.

Via Benzinga

The 7 Hottest Biotech Stocks to Own in 2023 and Beyond ↗

December 18, 2022

Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year.

Via InvestorPlace

SolarEdge To Rally 54%? Plus This Analyst Predicts $1,335 For Mettler-Toledo International ↗

November 08, 2022

Goldman Sachs raised the price target on Mettler-Toledo International Inc. (NYSE: MTD) from $1,120 to $1,335. Goldman Sachs analyst Matthew Sykes upgraded the stock from Sell to Neutral. Mettler-Toledo...

Via Benzinga

Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25% ↗

November 08, 2022

SVB Leerink raised the price target on Cigna Corporation (NYSE: CI) from $305 to $335. Cigna shares rose 0.7% to close at $324.37 on Monday.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.